Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
Purity: ≥98%
Maxacalcitol (22-Oxacalcitriol) is a novel analog of calcitriol that doesn't cause hypercalcemia. It can successfully prevent PTH synthesis because it is an agonist of the vitamin D3/2 receptor (VDR). Human orally bioavailable epithelial cells are stimulated to produce hCAP-18/LL-37 by maxacalcitol (OCT). Maxacalcitol Has Cardioprotective Properties in People with Diabetes Mellitus. By attracting PPM1A/VDR complex to pSmad3, maxacalcitol improves tubulointerstitial fibrosis in blocked kidneys.
References |
[4]. Successful Treatment of Bowen's Disease with Topical Maxacalcitol.Acta Derm Venereol. 2012 Jan 26. [5]. Effects of maxacalcitol ointment on skin lesions in patients with psoriasis receiving treatment with adalimumab. J Dermatol. 2016 Nov;43(11):1354-1357. doi: 10.1111/1346-8138.13515. Epub 2016 Jul 23. PubMed PMID: 27450634. |
---|
Molecular Formula |
C26H42O4
|
---|---|
Molecular Weight |
418.61
|
Exact Mass |
418.31
|
Elemental Analysis |
C, 74.60; H, 10.11; O, 15.29
|
CAS # |
103909-75-7
|
Related CAS # |
103909-75-7
|
Appearance |
Solid powder
|
SMILES |
C[C@@H]([C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)OCCC(C)(C)O
|
InChi Key |
DTXXSJZBSTYZKE-ZDQKKZTESA-N
|
InChi Code |
InChI=1S/C26H42O4/c1-17-20(15-21(27)16-24(17)28)9-8-19-7-6-12-26(5)22(10-11-23(19)26)18(2)30-14-13-25(3,4)29/h8-9,18,21-24,27-29H,1,6-7,10-16H2,2-5H3/b19-8+,20-9-/t18-,21+,22+,23-,24-,26+/m0/s1
|
Chemical Name |
(1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
|
Synonyms |
OCT; Maxacalcitol; Maxacalcitriol; MC 1275; Prezios; 22-Oxacalcitriol; Sch 209579; 22-Oxa-1,25-dihydroxyvitamin D3; alpha,25-Dihydroxy-22-oxavitamin D3
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~50 mg/mL (~119.4 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (3.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3889 mL | 11.9443 mL | 23.8886 mL | |
5 mM | 0.4778 mL | 2.3889 mL | 4.7777 mL | |
10 mM | 0.2389 mL | 1.1944 mL | 2.3889 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01341782 | Completed | Drug: maxacalcitol Drug: paricalcitol |
Secondary Hyperparathyroidism Hemodialysis |
AbbVie (prior sponsor, Abbott) |
May 2011 | Phase 3 |
NCT00990704 | Completed | Drug: paricalcitol Drug: maxacalcitol |
Secondary Hyperparathyroidism Hemodialysis |
Abbott | October 2009 | Phase 2 |
NCT00667576 | Completed | Drug: paricalcitol Drug: Maxacalcitol |
Chronic Kidney Disease on Hemodialysis Secondary Hyperparathyroidism |
Abbott | April 2008 | Phase 2 |